The pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories at three dosage strengths and oral syrup were studied. The study had an open-label, randomized ...

The purpose of this study was to evaluate the pharmacokinetics of intranasal hydromorphone hydrochloride (HCl) in patients with vasomotor rhinitis. Methods: Ten patients completed the randomised ...

The first-in-human trial with FE 999049 was a randomised, double-blind, placebo-controlled, sequential single-dose escalation trial investigating the safety, tolerability and pharmacokinetics. A Phase ...

The study will assess the drug's safety, tolerability, pharmacokinetics and pharmacodynamics in obstructive HCM patients.

U S-based biopharmaceutical company VYNE Therapeutics has received US Food and Drug Administration clearance for its investigational new drug (IND) application for VYN202, allowing it to begin a Phase ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human ...

The US FDA has granted fast track designation for iECURE’s ECUR-506 for the treatment of neonatal onset ornithine transcarbamylase deficiency.

The Phase 1 study will evaluate single and multiple ascending doses of travatrelvir in a double-blinded, placebo-controlled study to assess safety, tolerability, and pharmacokinetics. Subjects will be ...

As this is the first in pediatric study, the objective of the first part is to evaluate the safety and pharmacokinetics of ...

The first patient is expected to be enrolled in a Phase 1 trial to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity in the second quarter of 2024. The global launch of NGENLA ® ...

BG-68501 (CDK2 inhibitor): Initiated second dose level of monotherapy in first-in-human study, with clinical pharmacokinetics as expected and no dose limiting toxicities observed. BG-C9074 (B7H4 ADC): ...

Exploring the robust financial positioning and strategic developments of Aclaris Therapeutics in the first quarter of 2024.